Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

Outcomes of SGLT2 inhibitors in patients with polycystic kidney disease and diabetes

Impact of SGLT2 inhibitors on kidney health and survival in patients with polycystic kidney disease and type 2 diabetes.

Diabetes research and clinical practice

Citation & Authors

Diabetes Res Clin Pract. 2025;226:112357.

Fu-Shun Yen; Jing-Yang Huang; Chen Dong; Chii-Min Hwu; Chih-Cheng Hsu; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

This TriNetX target trial emulation compared SGLT2 inhibitors with nonuse, DPP-4 inhibitors, and GLP-1 drugs. Dialysis risk was lower in all three comparisons (HRs 0.657, 0.458, and 0.531, respectively). Acute kidney injury and death were also less frequent than among nonusers and DPP-4 inhibitor users. The study relies on medical records and matching methods and cannot directly replace randomized trials specifically in polycystic kidney disease.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗